Price (GBX)
92.50 -11.90% (-12.50)
SNGORD 1P
Track 1 instrument
Open / Last close
105.00 / 92.50
High / Low
105.00 / 90.50
Bid / Offer
92.00 / 93.00
Turnover
£1,943,476.00
Special Condition: -
Trading Status: Market Close
As at 23.11.20 21:46:14 - All data delayed at least 15 minutes

Synairgen plc instruments

Select instrument to view
Equity (1)
Code Instrument name Price Change Type Documentation
SNGORD 1P92.50
GBX
-11.90%Equity-

Price information

What's this?
Open price
105.00
Previous close price / date
92.50 / 23 November 2020
Volume
6,304,861
Turnover (on book)
£1,943,476.00
52 week range
5.88 / 249.00
YTD return
1,474.47
1 year return
1,074.60

Instrument information

What's this?
Market
AIM
Instrument market cap (£m)
209.91
Earnings per share
-0.04
Issue date
23 June 2005
ISIN
GB00B0381Z20
SEDOL
B0381Z2
Market identifier code (MIC)
AIMX
Country of share register
GB
Market segment
AMSM
Trading service
SETS
Nominated Advisers
Date Time Price CurrencyVolume Trade ValueTrade type Trade flag MIC
23.11.20 16:29:12 93.00 GBX 15,000 13,950.00 Off-Book LRGS SINT
23.11.20 16:23:04 92.60 GBX 20,000 18,520.00 Off-Book LRGS AIMX
23.11.20 16:21:32 93.40 GBX 21,399 19,986.45 Off-Book LRGS AIMX
23.11.20 16:14:12 92.60 GBX 15,000 13,890.00 Off-Book LRGS AIMX
23.11.20 16:08:01 93.00 GBX 15,000 13,949.25 Off-Book LRGS AIMX

Equity Research

from Synairgen plc
Rude Health - finnCap Life Sciences quarterly sector note

Oxford University and AstraZeneca announced the first interim analysis from the Phase III study of its COVID-19 vaccine candidate, which was found to be 70% effective in preventing COVID-19. This follows similar announcements from Moderna, and Pfizer/BioNTech in the previous two weeks, and the cavea ...

View report
Synairgen - £80m funding for COVID-19 study and supply chain

Synairgen has raised £80m to fund a Phase III trial for SNG001 in COVID-19 disease, which is due to commence in Q4 2020 and will be run globally by Parexel, with results expected in Q2 2021, and scale up manufacturing. This follows a successful pre-IND meeting with the FDA, which provided the guidan ...

View report
Morning Note – 29 September 2020

Chariot Oil & Gas (CHAR): Corp | dotDigital (DOTD): Corp | Gateley (GTLY): Corp | Iofina (IOF): Corp | Synairgen (SNG): Corp | Universe Group (UNG): Corp

View report
Synairgen - Interims and fuller Phase II data analysis

Synairgen reported interim results to 30 June in which the adjusted net loss was £3.9m with period-end cash of £10.9m. A fuller analysis and disclosure of the Phase II trial of inhaled interferon (SNG001) in hospitalised COVID-19 patients confirms the earlier optimism we had at the ti ...

View report
SP Angel Healthcare Conditions

Synairgen (SNG.L): Positive interim data from trial of SNG001 in COPD patients | Silence Therapeutics (SLN.L): R&D Update | Verona Pharma plc (AIM: VRP.L): Initation of pilot study in COVID-19 patients

View report
Issuer presentations live and on demand
Watch on Spark Live